Drug Price & Availability Router
Discovery Lens
C Combination Innovation
Two separate worlds finally connect — and the intersection is a product
One-Liner
AI that finds the cheapest legal source for any prescription medication, including options GoodRx doesn't cover.
Kill Reason
GoodRx has 25M+ monthly users and Cost Plus Drugs specifically targets the 'drugs GoodRx doesn't cover well' gap, meaning this is a feature addition to an existing dominant player rather than a greenfield opportunity. Pharmacy discount networks require negotiated contracts with PBMs and pharmacy chains — the barrier is relationships and volume, not data aggregation — giving incumbents a structural moat this product cannot replicate.
What do you think?
Related ideas you can explore free:
killed: Consumer spectroscopy hardware at the $50–100 price point cannot reliably detect food contaminants — this is a documented technical limitation that already killed SCiO ($23M raised), Tellspec, and Consumer Physics before them. At the accuracy levels achievable with phone-attachment optical sensors, false-positive rates would be high enough to make the product dangerous as a safety device and useless as a consumer gadget. FDA regulation of food safety testing devices would require clinical validation the physics cannot support.
killed: The consumer water filtration and testing market is dominated by Brita, ZeroWater, and Culligan, all of which are adding PFAS-reduction claims to their products. The personalized AI layer doesn't create a defensible moat — any filter company can add an app, and the actual testing hardware for lab-grade PFAS detection remains expensive and regulated.
killed: Distributed AI inference across local networks is an active open-source development area — Petals, ExLlamaV2, and llama.cpp all address this problem, and NVIDIA and AMD are solving the same constraint with hardware. The business model is unclear: who pays for software to pool RAM when cloud inference is cheaper and simpler for most use cases?